Table 1.

FDA approved combinations of checkpoint inhibition plus angiogenesis inhibitors

Immune checkpoint inhibitor	Anti-angiogenic compound	Cancer type	Approval date	Trial registration number [reference]
Atezolizumab	Bevacizumab + chemotherapy	Advanced non-squamous NSCLC	December 6th, 2018	NCT02366143 [332]
Pembrolizumab	Axitinib	Renal cell carcinoma	April 19th, 2019	NCT02853331 [156]
Avelumab	Axitinib	Advanced renal cell carcinoma	May 14th, 2019	NCT02684006 [331]
Pembrolizumab	Lenvatinib	Advanced endometrial carcinoma	September 17th, 2019	NCT02501096 [333]
Atezolizumab	Bevacizumab	Hepatocellular carcinoma	May 29th, 2020	NCT03434379 [157]
Nivolumab	Cabozantinib	Renal cell carcinoma	January 22nd, 2021	NCT03141177 [383]
Pembrolizumab Pembrolizumab	Lenvatinib Lenvatinib	Endometrial cancer Advanced renal cell carcinoma	July 21st, 2021 August 10th, 2021	NCT03517449 [384] NCT02811861 [385]

Atezolizumab (anti-PD-L1 antibody); Pembrolizumab (anti-PD-1 antibody); Avelumab (anti-PD-L1 antibody); Nivolumab (anti-PD-1 antibody); Bevacizumab (anti-VEGF antibody); Axitinib (tyrosine kinase inhibitor of VEGFR1-3); Lenvatinib (tyrosine kinase inhibitor of VEGFR1-3, FGFR1-4, PDGFR, c-Kit, RET); Cabozantinib (small molecule inhibitor of the kinase receptors c-Met, VEGFR2 and AXL); NSCLC non-small cell lung cancer